5 - 8 October 2009, Palais de Congrès de Lyon, Lyon, France

Hear from:

Dr Ole Olesen
Scientific Officer, Neglected Infectious Diseases
Infectious Diseases Unit, DG-Research
European Commission

Dr Pierluigi Lopalco
Senior Expert, Scientific Advice Unit
European Centre for Disease Prevention and Control

Didier Hoch
President, sanofi pasteur MSD and Former President, European Vaccine Manufacturers

Dr Philippe Dro
Chief Executive Officer
GlycoVaxyn

Dr Matthias Schroff
Chief Executive Officer
Mologen

World health

Innovation and opportunity for pharma, biotechs, healthcare and investors

Representation from key European Commission and regulatory agencies
DG Research, DG SANCO, ECDC, EDQM, CHMP, VWP, MHRA, PEI, FAMHP and MEB provide vision and clarity on future industry progress and opportunities

Europe’s largest commercial vaccine industry congress for decision makers across European and North America regions
Including World class multiple speaker representation from Baxter, GSK Biologicals, MedImmune, Novartis Vaccines and Diagnostics, Pfizer, sanofi pasteur, sanofi pasteur MSD, Solvay and Wyeth Vaccines

Critical market opportunities outlined in billion Euro vaccine market
European policy frameworks, vaccine regulation and authorisation, vaccine R&D innovation and introduction, Influenza market sustainability, corporate growth strategies and funding sources

1-2-1 partnering opportunities with “Contact”
Schedule dedicated onsite meetings with partners and gain the visibility your company needs.

Sponsors:

www.lifescienceworld.com/2009/wvcl

BOOK NOW! online www.lifescienceworld.com/2009/wvcl | email sarah.pegden@terrapinn.com | phone +44 (0)20 7242 2324 | fax +44 (0)20 7242 2320
Europe’s largest and most influential vaccine congress

Vaccines: a market and industry on the rise

These are electrifying times for the European vaccine industry. With the European market for vaccines set to grow to an unprecedented Euro 4.97 billion by 2012, it represents a compound annual growth rate of 10.8 per cent over the next 3 years. With similar predictions for the pharmaceutical industry unlikely during the same period, the vaccine market continues to remain a very prosperous field.

While the number of diseases covered by vaccines available in Europe have not increased significantly in the past few years, the introduction and development of novel and improved products, especially for new diseases such as HPV, rotavirus, pneumococcal and meningococcal, are driving the overall market.

With the major players aiming their vaccine development programmes at the adolescent and adult groups, it is a strategy that is likely to be followed by the majority of vaccine manufacturers in Europe for the long term. Furthermore, enterprises in Western European countries continue to focus more and more on establishing greater diversity in therapeutic and preventive vaccine pipelines, a development that will likely continue to stimulate the region’s vaccine market.

Hear from the World’s leading business leaders and vaccine stakeholders

The 11th annual World Vaccine Congress Lyon is Europe’s largest event addressing the research and development and commercial manufacture of vaccines across the therapeutic and prophylactic landscape. Featuring the most influential and innovative industry and business leaders from European agencies, global big pharma and biotechs, this lively and energetic meeting combines experts’ keynotes, cutting-edge case studies and dedicated 1-2-1 networking in a deal-making environment where debate is encouraged and discussion thrives.

The congress covers the advancing markets of therapeutic and prophylactic candidates against a target demographic of pediatric, adolescent and adult recipients. With an increased and highly significant level of involvement from big pharma this year, participant companies in the 2009 speaker faculty include Baxter, GSK Biologicals, MedImmune, Novartis Vaccines and Diagnostics, Pfizer, sanofi pasteur, sanofi pasteur MSD, Solvay and Wyeth Vaccines, plus presence from Intercell and Crucell.

Capitalise on the resurgence of an industry continuing to write new success stories every day, and attend the region’s number one event for major vaccine players and their respective senior level representatives. Officially the longest-running and largest vaccine event in Europe, World Vaccine Congress Lyon continues to deliver a forum where you meet more of the World’s most compelling and influential scientific and strategic leaders, facilitating education, debate and business.

World class industry stakeholders leading the 2009 speaker faculty

Dr Ole Olesen  
Scientific Officer, Neglected Infectious Diseases, Infectious Diseases Unit, DG-Research, European Commission

Dr Allan Jarvis  
Senior Vice President, Corporate Development sanofi pasteur

Dr Frederic Lehmann  
Director, Clinical Research and Development GSK Biologicals

Dr Pierluigi Lopalco  
Senior Expert, Scientific Advice Unit European Centre for Disease Prevention and Control

Dr Beatrice de Vos  
Vice President, Global Scientific and Medical Affairs sanofi pasteur

Didier Hoch  
President, sanofi pasteur MSD and Former President, European Vaccine Manufacturers

Dr Patrick Caubel  
Vice President, Head Global Pharmacovigilance sanofi pasteur

Dr Nathalie Garçon  
Vice President, Head of Research and North America R&D GSK Biologicals

Didier Hoch  
President, sanofi pasteur MSD and Former President, European Vaccine Manufacturers

Dr Beatrice de Vos  
Vice President, Global Scientific and Medical Affairs sanofi pasteur

Dr Patrick Caubel  
Vice President, Head Global Pharmacovigilance sanofi pasteur

Didier Hoch  
President, sanofi pasteur MSD and Former President, European Vaccine Manufacturers

Dr Nathalie Garçon  
Vice President, Head of Research and North America R&D GSK Biologicals

Dr Joe Cohen  
Vice President R&D, Head of Vaccines for Emerging Diseases and HIV GSK Biologicals

Dr Jeffrey Ulmer  
Global Head of External Research Novartis Vaccines and Diagnostics

Dr Luc Hessel  
Executive Director, Medical and Public Affairs, Europe sanofi pasteur MSD

Dr Peter Dull  
Head of Department, Meningococcal Conjugate Vaccines Novartis Vaccines & Diagnostics

Dr Joe Cohen  
Vice President R&D, Head of Vaccines for Emerging Diseases and HIV GSK Biologicals

Dr Jeffrey Ulmer  
Global Head of External Research Novartis Vaccines and Diagnostics

Dr Luc Hessel  
Executive Director, Medical and Public Affairs, Europe sanofi pasteur MSD

Dr Peter Dull  
Head of Department, Meningococcal Conjugate Vaccines Novartis Vaccines & Diagnostics
Europe’s premier vaccine congress, World Vaccine Congress Lyon, brings together decision-makers from leading vaccine pharmaceutical, biotechnology and contract service companies from around the world for 4 days of focused networking, presentations, expert panels and 1-2-1 partnering.

No other vaccine industry event this year matches the exclusive access to the industry’s major players that World Vaccine Congress Lyon offers. Providing you with more mediums to facilitate the all important business negotiations, and with over 15 hours of dedicated face-to-face time with your peers and prospective clients, we will help you strengthen your corporate identity and visibility.

To celebrate this year’s World Vaccine Congress Lyon we will be hosting a Gala Dinner at the renowned Brasserie Georges following the conference programme on the 6th October, a monument of Lyonnaise gastronomy since 1836, the oldest in Lyon.

**EUROPEAN VACCINE EVALUATION AND AUTHORISATION**

**08.30** Registration and morning coffee  
**09.30** Chairman’s opening remarks  
**09.40** Keynote address: how is the environment for European vaccine research and development stimulating industry?  
Dr Ole Olesen, Scientific Officer, Neglected Infectious Diseases, Infectious Diseases Unit, DG-Research, European Commission

**10.40** What contribution is the European Centre for Disease Control and Prevention making in operating on vaccination policy?  
Dr Pierluigi Lopalco, Senior Expert, Scientific Advice Unit, European Centre for Disease Prevention and Control

**11.10** Panel session: what implication do future vaccine plans, frameworks and initiatives have on industry?  
Dr Ole Olesen, Scientific Officer, Neglected Infectious Diseases, Infectious Diseases Unit, DG-Research, European Commission  
Anton Gijsehs, Policy Officer, Unit C3 - Health Threats, Directorate C, Public Health and Risk Assessment, European Commission  
Dr Hans van Gompel, Medicines Evaluation Board, The Netherlands

**10.10** Identifying DG SANCO initiatives: enhancing industry cooperation on the introduction of new vaccines  
Anton Gijsehs, Policy Officer, Unit C3 - Health Threats, Directorate C, Public Health and Risk Assessment, European Commission  
Dr Olesen, Scientific Officer, Neglected Infectious Diseases, Infectious Diseases Unit, DG-Research, European Commission  
Dr Katherine Cohen, Head of Section, Microbial Vaccines, FAMHP, Belgium

**12.40** How are vaccine authorisations influenced by the EDQM and European Pharmacopoeia?  
Dr Jean-Marc Spieser, Director, Biological Standardisation Department, EDQM, Council of Europe

**12.10** How are emerging vaccine therapies authorised under evolving European centralised authorisation procedures?  
Representative to be confirmed, EMEA

**13.10** Networking lunch

**14.30** Overcoming decentralised national challenges to resolve vaccine authorisation and assessment  
Dr Hans van Gompel, Senior Regulatory Project Leader, Medicines Evaluation Board, The Netherlands

**15.00** Identifying ongoing VWP initiatives and facilitating ongoing marketing authorisation applications  
Dr Pieter Neels, FAMHP, Belgium and Co-Chair, Vaccine Working Party, CHMP

**15.30** Afternoon tea

**16.00** Panel session: what are key European Member State approaches to vaccination authorisation?  
Dr Mair Powell, Medical Assessor, Licensing Division, MHRA  
Dr Volker Öppling, Head of Section, Microbial Vaccines, PEI  
Dr Pieter Neels, FAMHP, Belgium and Co-Chair, Vaccine Working Party, CHMP

**16.40** What role can European vaccine manufacturers play in facilitating vaccination policy?  
Didier Hoch, President, sanofi pasteur MSD and Former President, EVM

**17.10** Close of congress day followed by networking drinks
Congress Day 1 Tuesday 6 October 2009

AN EVOLVING ROLE FOR BIG PHARMA

09.00 Chairman’s opening remarks
09.10 Vaccine sector growth: are innovative investing models the answer to addressing vaccine market demand
Dr Eric Le Berrigaud, Equity Analyst – Pharmaceutical, Raymond James Euro Equities
09.40 How to overcome existing challenges for vaccine manufacturers driving growth through innovation
Didier Hoch, President, sanofi pasteur MSD and Former President, EVM

VACCINE CORPORATE GROWTH STRATEGIES

10.10 Cross border strategic growth and acquisition strategies
Dr Jeff Southerton, Executive Director, Worldwide Business Development, Pfizer Global R&D
10.40 Morning coffee

11.10 Innovative acquisitions and the key to success for pharma and biotech models: sanofi pasteur and Acambis
Dr Allan Jarvis, SVP, Corporate Development, sanofi pasteur
11.40 How biotechs can consolidate growth during times of market consolidation: the Intercell / IOMAI perspective
Dr Katherine Cohen, VP, Corporate and Business Development, Intercell

12.10 Panel session: where are Big Pharma and biotech focusing and pursuing corporate development opportunities?
Dr Jeff Southerton, Executive Director, Worldwide Business Development, Pfizer Global R&D
Dr Allan Jarvis, SVP, Corporate Development, sanofi pasteur
Dr Jeffrey Ulmer, Global Head of External Research, Novartis Vaccines and Diagnostics
Dr Katherine Cohen, VP, Corporate and Business Development, Intercell
12.50 Networking lunch

STREAM 1

BIOTECH START-UP INNOVATION SHOWCASES

13.50 A novel type of live vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist
Dr Thomas Muster, Chief Executive Officer, AVIR Green Hills Biotechnology
14.05 Novel infectious disease and Campylobacter vaccines
Dr Ingelise Saunders, Chief Executive Officer, ACE Biosciences
14.20 Fostering clinical development for HIV Vaccines
Dr Kalevi Reijonen, Chief Executive Officer, FIT Biotech
14.35 Pre-clinical prostate- and B-cell lymphoma cancer vaccines
Dr Ole Henrik Brekke, Chief Executive Officer, Vaccibody
14.50 Establishing novel Meningitis B vaccine development
Dr Graham Clarke, Chief Executive Officer, ImmBio Ltd.
15.05 Meet 120 attendees in just 60 mins
15.30 Meet 120 attendees in just 60 mins
16.30 Afternoon tea

VACCINE INTRODUCTION REVIEW

17.00 Current needs of benefit and risk management post-marketing for recently introduced vaccines
Dr Guy Demol, Executive Director, Medical & Scientific Affairs, sanofi pasteur MSD and Chair, Risk Management and Pharmacovigilance Working Group, EVM
17.30 Evolution of Meningococcal conjugateACYW135
Dr Peter Dull, Head of Department, Meningococcal Conjugate Vaccines, Novartis Vaccines & Diagnostics
18.00 Clinical updates for investigational 13-valent PVC
Dr Susan Tansey, Director, Clinical Research, Wyeth Vaccines

18.30 Close of congress day followed by a GALA at Brasserie Georges
**Congress Day 2  Wednesday 7 October 2009**

**THE FUTURE DIRECTION OF VACCINE R&D**

**STREAM 1**

09.00 Chairman’s opening remarks

09.10 Innovation and market access: promoting rapid access to innovative vaccines in the EU  
Dr Rudi Daems, Director, Policy & Partnerships, GSK Biologicals

09.40 How is clinical development progressing for Neisseria Meningitidis B vaccine development?  
Dr Peter Dull, Head of Department, Meningococcal Conjugate Vaccines, Novartis Vaccines & Diagnostics

10.10 Innovative approaches to RSV vaccine development and VLP based vaccines  
Dr Rahul Singhvi, Chief Executive Officer, Novavax

10.40 Morning coffee

11.20 Novel vaccine technology against staphylococcus aureus  
Dr Raafat Fahim, Chief Executive Officer, Nabi Biopharmaceuticals

11.50 Assessing clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma  
Dr Freder Lehmann, Director, Clinical Research and Development, GSK Biologicals

12.20 How are hepatitis B vaccine candidates demonstrating the potential to provide increased protection?  
Dr Melissa Malhame, Project Leader HEPLISAV, Dynavax Technologies

12.50 Networking lunch

14.10 Pursuing in parallel Immunodrug™ programs addressing important chronic disease indications  
Dr Martin Bachmann, Chief Scientific Officer, Cytos Biotechnology

14.40 What targets are advancing TB vaccine development?  
Dr Leander Grode, Project Manager and Director, Business Development, Vakzine Projekt Management

15.10 Identifying promising and novel approaches to Malaria vaccine studies  
Dr Odile Leroy, Director of Clinical and Regulatory Affairs, Statens Serum Institut and Executive Director, European Malaria Vaccine Initiative

15.40 Afternoon tea

16.10 Key industry investigations HIV vaccine development  
Dr Joe Cohen, Vice President R&D, Head of Vaccines for Emerging Diseases and HIV, GSK Biologicals

16.40 Making headway on Shigella vaccine R&D  
Dr Armelle Phalipon, Director, Molecular Microbial Pathogenesis Unit, Institut Pasteur

17.10 Viable candidate development for Dengue Fever vaccine  
Dr Dan Stinchcomb, Chief Executive Officer, Inviragen

17.40 Close of congress day followed by networking drinks

**OR**

**STREAM 2**

09.00 Chairman’s opening remarks

09.10 Specificities of developing a novel influenza vaccine with unusual preclinical / clinical investigations  
Dr Martine Denis, Senior Director, Clinical Development, Influenza Vaccines, sanofi pasteur

09.40 Interpreting Clinical safety and effectiveness of adjuvanted vaccines  
Dr Angelika Banzhoff, Head European Pharmacovigilance, Clinical Trial Safety and Risk Assessment, EU/EEA QPPV, Novartis Vaccines and Diagnostics

10.10 Rational design and standardised evaluation of novel genetic vaccines: avenues to systems biology  
Dr David Klatzmann, Professor of Immunology, UPMC

10.40 Morning coffee

**VACCINE CLINICAL DEVELOPMENT COMPLEXITIES**

11.20 Critical process parameters to maximise vaccine yield and quality  
Dr Catarina Flyborg, Leader Vaccine Initiatives, GE Healthcare Life Sciences

11.50 Transition to bioprocess and new generation  
Dr Vittoria Pellegrini, Head, Technical and Business Affairs, Novartis Vaccines & Diagnostics

12.20 New technologies for flexible vaccine production  
Robert Shaw, Director, Strategic Marketing and WW Training Program Director, Vaccines and Emerging Biotech, Millipore

12.50 Networking lunch

14.10 A benchmark for economic vaccine scale-up strategies  
Dr Simon Hsu, Principal Scientist, Vaccine Process Biochemistry, MedImmune

14.40 End-to-end process development and scaleable manufacture  
Dr Phil Ball, Technical Director, USA, Eden Biodesign

15.10 Mechanisms for vaccine production supply into the EU  
Dr Tarit Mukhopadhyay, Lecturer, Vaccine Bioprocess Development, University College London

15.40 Afternoon tea

**MANUFACTURE, PROCESS DEVELOPMENT AND SCALE-UP**

16.10 Cell-culture derived vaccine technology advances  
Dr Otfried Kistner, Senior Director Virology / Viral Vaccines, Baxter BioScience

16.40 How to advance manufacturing using scalable solutions  
Jim Robinson, Vice President, Technical Operations and Quality Operations, Novavax

17.10 Scalable manufacture for virus and recombinant proteins  
Dr Stephen Brown, Director of Manufacturing, Vivalis
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Chairman’s opening remarks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.10</td>
<td>European approaches: current non-clinical testing requirements for adjuvants / adjuvanted vaccines</td>
<td>Dr Jan Willem van der Laan, Senior Assessor Pharmaceuticals, RIVM</td>
<td></td>
</tr>
<tr>
<td>09.40</td>
<td>Clinical experience and key steps leading to AS-adjuvanted vaccine registration</td>
<td>Dr Nathalie Garçon, VP, Head of Research and North America R&amp;D, GSK Biologicals</td>
<td></td>
</tr>
<tr>
<td>10.10</td>
<td>How to establish a mechanism of action of TLR-dependent and independent adjuvants</td>
<td>Dr Ennio de Gregorio, Head of Immunology, Novartis Vaccines &amp; Diagnostics</td>
<td></td>
</tr>
<tr>
<td>10.40</td>
<td>Morning coffee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.10</td>
<td>Outlining novel cellular adjuvant products for therapeutic vaccines against cancer</td>
<td>Dr Vincent Serra, Chief Executive Officer, Wittecyell</td>
<td></td>
</tr>
<tr>
<td>11.40</td>
<td>Examining global regulatory frameworks for novel vaccine introduction into regional markets</td>
<td>Stéphane Callewaert, Manager, Worldwide Vaccine Registration Management, GSK Biologicals</td>
<td></td>
</tr>
<tr>
<td>12.10</td>
<td>Panel session: how can you align strategies with regulation to avoid barriers to vaccine development?</td>
<td>Mary Allin, Senior Director, Regulatory Affairs, Wyeth Research, Eddie Reilly, Head, Regulatory Affairs Europe and International, Novartis Vaccines and Diagnostics, Stéphane Callewaert, Manager, Worldwide Vaccine Registration Management, GSK Biologicals, Dr Hanna Nohynek, Senior Vaccine Consultant, Encorium</td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>Networking lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00</td>
<td>Exploiting industry procedures and strategies to enhance risk-benefit assessments and safety reporting</td>
<td>Dr Patrick Caubel, VP, Head Global Pharmacovigilance, sanofi pasteur</td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td>How to ensure structured post-marketing safety data and pharmacovigilance planning</td>
<td>Dr Thomas Verstraeten, VP, Head, Biologicals Clinical Safety and Pharmacovigilance GSK Biologicals</td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td>From post-marketing surveillance to risk management</td>
<td>Dr Katharina Hartmann, Head of Pharmacovigilance, Crucell</td>
<td></td>
</tr>
<tr>
<td>15.30</td>
<td>Panel session: how can industry respond to unexpected quality and safety issues arising at late stages?</td>
<td>Dr Patrick Caubel, VP, Head Global Pharmacovigilance, sanofi pasteur, Dr Thomas Verstraeten, VP, Head, Biologicals Clinical Safety and Pharmacovigilance GSK Biologicals, Dr Katharina Hartmann, Head of Pharmacovigilance, Crucell</td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td>Close of congress followed by afternoon tea.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Becoming a sponsor

World Vaccine Congress Lyon 2009 is where your clients will come to look for solutions - solutions you can provide. The World Vaccine Congress Lyon will attract the biggest gathering of vaccine businesses to assemble in 2009 in the European region. How are you going to make sure you stand out from the crowd? The simple answer is to invest in the event, invest in your company’s future and make sure your client base knows who you are.

Your direct route to market

World Vaccine Congress Lyon is the number one platform for world class vendors and solution providers, to showcase their products and expertise to the biggest ever targeted vaccine audience. This could be your chance to be part of the most cost-effective marketing solution in the vaccine industry. Reduce the time taken to meet new customers, reduce the costs of advertising and maximise the return on your investment.

Who should sponsor and exhibit?

World Vaccine Congress Lyon offers a total marketing and business development solution to companies looking to position themselves at the forefront of the vaccine industry, generate more leads and increase their company’s revenue.

- CROs
- CMOs
- EQMs
- Drug delivery
- Clinical trial sites
- Platform providers
- Global consultants
- Biotechs

Delivering real results

No other event can give you exclusive access to senior decision makers from key vaccine, pharmaceutical, biotech companies and government bodies. Sponsoring or exhibiting at World Vaccine Congress Lyon is an exceptional opportunity to be part of a 24/7 targeted marketing campaign that not only guarantees a quality audience but also keeps your target markets informed about you.

With one cost-effective investment, World Vaccine Congress Lyon will enable you to:

- Start meeting your strategic objectives for the year ahead by putting your company on a platform
- Demonstrate your thought leadership position in the market
- Discuss new product developments
- Conduct real business and build your brand with a group of highly qualified decision-makers
- Develop and reinforce key relationships
- Unrivalled lead generation and profiling
- Target your message to your precise audience

Major industry players have confirmed their early support for 2009. YOU should get organised too!

Contact us TODAY for a tailored sponsorship package to meet your business objectives:
Sylvester Gabriel, Commercial Manager
Tel: +44 (0) 20 7827 5994
Email: sylvester.gabriel@terrapinn.com

Sponsors and exhibitors include

Media partners

BOOK NOW! online www.lifescienceworld.com/2009/wvcl | email sarah.pegden@terrapinn.com | phone +44 (0)20 7242 2324 | fax +44 (0)20 7242 2320
Biotech Discounts

☑ Yes. I am a small / early stage biotech. Therefore qualify for an exclusive discount. Call Neil Darke's now to find out more details +44 (0)20 7242 1248.

Your voucher code (you'll need to quote this for telephone and online bookings)

All tickets include refreshments, lunch and full conference documentation. The fee does not include hotel accommodation.

Your details

Delegate name .......................................................... Organisation: ..........................................................

Job title .......................................................... Address ..........................................................

Post code .......................................................... Country: ..........................................................

Tel .......................................................... Fax: ..........................................................

Email: ..........................................................

Authorising manager: .......................................................... Authorising manager signature: ..........................................................

Payment details

Payment terms are 14 days from date of invoice. Notwithstanding this, payment must be received prior to the conference taking place. Kindly note the terms and conditions on our registration page.

☑ Bank transfer ☐ Invoice me ☐ Credit card ☐ Diners club ☐ Visa ☐ American express ☐ Mastercard

Card number (you'll need to quote this for telephone and online bookings) Expiry date: / /

Card holders name .......................................................... Card holders signature: ..........................................................


Don't forget huge discounts are available for group bookings and small biotechs. See above for details.